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Abstract
Purpose Preference-based measures are required to mea-
sure the impact of interventions for cost-effectiveness
analysis. This study assessed the psychometric perfor-
mance of the EQ-5D-3L in adults with uncontrolled focal
(partial-onset) seizures.
Methods Data from three Phase III studies of an
antiepileptic drug (adjunctive brivaracetam; n = 1095)
were used. Analysis included correlations between EQ-5D-
3L and Quality of Life in Epilepsy Inventory (QOLIE-31P)
and seizure frequency. Known group validity was based on
ability of the EQ-5D-3L to discriminate between baseline
QOLIE-31P total scores, seizure type and number of
antiepileptic drugs using effect sizes (ES). Responsiveness
assessed proportions reporting highest or lowest scores,
overall change using standardized response means (SRM)
and change by responder and clinician/patient evaluation
groups using ES.
Results Correlations were weak to moderate (q = 0.2–0.4)
between EQ-5D-3L dimensions and QOLIE-31P subscales,
apart from medication effects (q\ 0.1); seizure frequency
was not associated with either measure. Known group
analysis had small ES. A quarter (24.9%) of patients had a
baseline EQ-5D-3L utility score of 1 (full health) but lower
average QOLIE-31P scores. SRMs were small (\0.1) in
EQ-5D-3L compared with 0.1–0.4 for QOLIE-31P sub-
scales. Results across the studies were mixed for responder
status and clinician/patient evaluation of improvement for
EQ-5D-3L.
Conclusions EQ-5D-3L had weak-to-moderate correla-
tions with QOLIE-31P and varied with QOLIE-31P
severity groups, but showed less responsiveness than
QOLIE-31P. Given this lack of sensitivity, EQ-5D-3L may
not be appropriate for measuring the impact of interven-
tions in cost-effectiveness analysis in this population and
disease-specific preference-based measures may be more
appropriate.
Keywords EQ-5D-3L  Uncontrolled focal seizures 
QOLIE-31P  Validity  Quality of life
Introduction
Epilepsy is a heterogeneous group of central nervous sys-
tem disorders characterized by unpredictable recurrent
seizures [1]. Epilepsy can significantly affect patients’
health-related quality of life (HRQoL), including their
mental health, and role and social functioning [2]. Seizure
control can be achieved with antiepileptic drug (AED)
treatment [3, 4], but up to 30% of patients still have
uncontrolled seizures. HRQoL can also be affected by
AED-associated side effects even in controlled patients.
HRQoL measures used in epilepsy trials should capture
these varied effects.
Reimbursement agencies such as the National Institute
for Health and Care Excellence (NICE) in the UK require
effectiveness to be measured in terms of quality-adjusted
life years (QALYs) [5], which combines HRQoL with
Electronic supplementary material The online version of this
article (doi:10.1007/s11136-016-1483-3) contains supplementary
material, which is available to authorized users.
& Clara Mukuria
c.mukuria@sheffield.ac.uk
1 School of Health and Related Research, University of
Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA,
UK
2 UCB Pharma, Slough, UK
123
Qual Life Res
DOI 10.1007/s11136-016-1483-3
length of life. The quality of life component of QALYs can
be estimated using generic preference-based measures,
such as the EQ-5D-3L [6] and the Short Form 6 dimensions
(SF-6D) [7] which are recommended by some reimburse-
ment agencies such as NICE. EQ-5D-3L is the most widely
used generic preference-based measure. Generic prefer-
ence-based measures enable comparison across different
diseases and populations and, as such, ensure a consistent
basis for the assessment of cost-effectiveness. Alterna-
tively, disease-specific preference-based measures can be
used to generate QALYs, though these are not comparable
with QALY estimates derived from other instruments.
Where preference-based measures have not been used in
clinical trials, some reimbursement agencies such as NICE
allow mapping of data from disease-specific non-prefer-
ence-based measures, such as the epilepsy-specific Quality
of Life in Epilepsy Inventory (QOLIE-31P) [8], to generic
preference-based measures, for use in cost-effectiveness
analysis [5].
In order to generate robust cost-effectiveness data,
generic preference-based measures need to be validated in
the population of interest; this also applies when mapping
is to be used [9]. However, few mapping studies report
information on validity of the generic preference-based
measures used in their analysis. There is evidence that
generic preference-based measures do not adequately cover
dimensions of HRQoL affected by certain diseases,
including epilepsy, and as such are not usable. This cov-
erage issue was found in a study (n = 140) of patients
evaluated for epilepsy surgery [10]. Therefore, the primary
aim of this study was to examine the validity and respon-
siveness of the EQ-5D-3L in a large sample of patients
with epilepsy who had uncontrolled focal (partial-onset)
seizures and who were taking part in trials of an approved
antiepileptic drug. A secondary aim was to test mapping
from the QOLIE-31P to the EQ-5D-3L if the two measures
were shown to have sufficient overlap based on the psy-
chometric performance of EQ-5D-3L, although there are
no specific guidelines in the literature regarding what is
acceptable for mapping purposes [9].
Methods
Data sources
Analyses used data from three double-blind, randomized,
placebo-controlled, Phase III studies of adjunctive bri-
varacetam, which is approved as an adjunctive therapy for
focal seizures, in adults with uncontrolled focal seizures:
N01252 (NCT00490035) [11]; N01253 (NCT00464269)
[12]; N01254 (NCT00504881) [13]. The study designs
have previously been described in the literature [11–13].
Baseline characteristics of the patients revealed the
refractory nature of their epilepsy. Most patients had pre-
viously taken several other AEDs: 50.3% had 2–4 prior
AEDs, 14.8% had C5 prior AEDs, and 66.1% were taking
two concomitant AEDs. Mean time since diagnosis was
20.4–26.2 years, and patients reported a median of 1.8–2.9
focal seizures/week at baseline. All three studies used the
EQ-5D-3L and QOLIE-31P to measure HRQoL.
Measures and assessments
EQ-5D-3L
The EQ-5D-3L is a preference-based measure of health
status across five dimensions (mobility; self-care; usual
activities; pain/discomfort; and anxiety/depression), each
with three severity levels (no problems, some problems,
and extreme problems). This results in a total of 243 pos-
sible ‘health states’, i.e. combinations of dimensions and
severity levels. A subset of the health states has been
evaluated in the general population and modelled to pro-
vide the utility tariff for each health state, where 1 repre-
sents full health, 0 represents dead and scores below 0
‘worse than dead’. In this analysis, the UK tariff was
applied, which ranges from -0.594 to 1 [14].
QOLIE-31P
The QOLIE-31P is a non-preference-based questionnaire
adapted from the QOLIE-31 which includes 30 items
grouped into seven subscales: energy/fatigue (4 items);
emotional well-being (5 items); daily activities/social
functioning (5 items); cognitive functioning (6 items);
medication effects (3 items); seizure worry (5 items);
overall quality of life (2 items); and a health status item. It
also includes 7 items on the degree of ‘distress’ for each
subscale topic and a ‘prioritization’ item on the relative
importance of each subscale topic. The total score is a
weighted sum of the subscale scores. Scores range from 0
to 100, with higher scores representing better functioning
[15].
Patients without mental impairment (as judged by the
investigator) in the three brivaracetam trials self-completed
the EQ-5D-3L and QOLIE-31P questionnaires at baseline
and at weeks 4, 8 and 12 (plus week 16 in N01254). Data
analysed were from baseline and week 12 (week 16 for
N01254).
Seizure frequency, severity and type
Patients completed daily seizure record cards, including
date, time, frequency, type of seizures and occurrence of
seizure clusters. Record cards were reviewed at visits to
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ensure completeness and accuracy. Focal seizures were
classified as simple, complex or secondarily generalized
[16]. The presence of the latter was used in this analysis as
a proxy for disease severity.
Number of prior AEDs
The number of different AEDs used in the past 5 years was
recorded at baseline. Patients with more prior AEDs could
be considered more treatment refractory, which in turn
could be related to baseline HRQoL.
Patient’s and Clinician’s Global Evaluation Scales (PGES/
CGES)
At weeks 12 or 16, patients without mental impairment
completed the patient global evaluation scale (PGES).
Investigators completed the clinician global evaluation
scale (CGES). Patients were asked ‘Overall, has there been
a change in your seizures since the start of the study
medication?’. Investigators were asked to ‘Assess the
overall change in the severity of the patient’s illness,
compared with the start of study medication’. Response
options ranged from ‘marked improvement’ (7) to ‘marked
worsening’ (1), with a score of 4 representing ‘no change’.
In all three trials, very few respondents reported marked
(1), moderate (2) or slight worsening (3) in either PGES
(B7%) or CGES (B4%); these options were therefore
combined with the ‘no change’ category in this analysis.
Analysis
Construct validity
Construct validity measures how well an instrument assesses
what it was intended to assess. Assessment of construct
validity relies on techniques that provide information on
whether the instrument is related to or converges with other
measures that cover constructs of interest, referred to as
convergent validity, as well as whether an instrument is able
to distinguish between groups that have known differences
(known group validity). The study aimed to assess whether
EQ-5D-3L would be appropriate for assessing the impact of
epilepsy, treatment and potential side effects on HRQoL. A
disease-specific measure, the QOLIE-31P, and other indi-
cators such as presence and number of seizures were used as
the basis of the assessment.
Convergent validity examined the correlation between
EQ-5D-3L and QOLIE-31P for both overall and dimen-
sion/subscale scores, and the correlation between each mea-
sure and seizure frequency using Pearson’s (between EQ-5D-
3L utility score and QOLIE-31P scores with seizure fre-
quency) or Spearman’s rank (between EQ-5D-3L dimensions
and seizure frequency) correlations. Cohen’s d cut-offs were
used to assess the strength of correlations: C0.5, strong; C0.3
to \0.5, moderate; \0.3, weak [17]. Moderate-to-strong
correlations were expected where HRQoL concepts were
considered to be related including the QOLIE-31P emotional
well-being and seizure worry scores with the EQ-5D-3L
anxiety/depression score, and the QOLIE-31-P daily activi-
ties/social functioning and energy/fatigue scores with the EQ-
5D-3L usual activities score.
Known group validity analysis assessed the ability of the
EQ-5D-3L to discriminate between groups expected to
differ in HRQoL at baseline, based on QOLIE-31P and
other measures of severity:
• QOLIE-31P scores of 0–40, 41–50, 51–60, 61–70 and
71–100 were used to represent severity groups; the
categorization reflects the QOLIE-31P total score
distribution as there were no published cut-offs. This
provided additional information to correlation analysis
on whether EQ-5D-3L performed in a similar way
across the QOLIE-31P total score range
• Presence of secondarily generalized focal seizures
during baseline (yes, no) (proxy for severe epilepsy)
• Presence of seizures on the day of completing the
instrument (yes, no)
• Baseline focal seizure frequency/week (\1, 1–\2, C2)
• Number of prior AEDs (0–1, 2–4).
Mean differences and effect sizes (ES; mean difference/
pooled standard deviation [SD]) across severity subgroups
were calculated for these variables. ES cut-offs were
defined as: 0.2–\0.5, small; 0.5–\0.8, medium; C0.8, large
[17]. One-way analysis of variance (ANOVA) or t tests
were used to assess differences in EQ-5D-3L utility scores
and QOLIE-31P total scores. As EQ-5D-3L utility scores
were not distributed normally, they were also assessed
using the nonparametric Kruskal–Wallis and Mann–Whit-
ney tests. Statistical significance was based on a = 0.05.
Baseline QOLIE-31P scores of patients with an EQ-5D-3L
utility score of 1 (best possible health status) were also
assessed to provide information on how well the EQ-5D-3L
classified patients.
Pooled baseline data for patients with no missing EQ-
5D-3L or QOLIE-31P data (n = 1095, 97% of the total
sample) were used to assess convergent and known group
validity.
Responsiveness
Responsiveness is the ability of an instrument to detect
changes. In order to do so, a measure should be sensitive
enough to reflect the dimensions of concern as well as the
full range of severity in a given population. It should also
reflect change where it has occurred.
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The proportion of individuals reporting the lowest or
highest scores at baseline was examined in EQ-5D-3L
dimensions compared to QOLIE-31P dimensions. If the
majority of individuals are at the highest score, this may
indicate that the dimension is not relevant or sensitive
enough particularly if other measures are sensitive enough
to detect problems in the same population. Lack of sensi-
tivity has an impact on the ability of the instrument to
detect improvements while a large proportion at the lowest
score makes it difficult to detect deterioration.
Mean change and standardized response means (SRM;
mean change/change SD) in EQ-5D-3L utility scores and
QOLIE-31P total and subscale scores from baseline to
follow-up were calculated. SRMs were compared across
both measures as small SRMs may reflect lack of change in
the group rather than lack of responsiveness of the EQ-5D-
3L. SRM cut-offs were defined as: 0.2–\0.5, small; 0.5–
\0.8, medium; C0.8, large [17].
Responsiveness was based on change in EQ-5D-3L
utility scores and QOLIE-31P total scores for: responders
(C50% reduction in focal seizure frequency at follow-up)
vs non-responders; PGES (scores of 1–4 vs. 5 vs. 6 vs. 7);
and CGES (scores of 1–4 vs. 5 vs. 6 vs. 7). Both PGES and
CGES are reported as there may be differences in patient
and investigator perception of change. One-way ANOVA
or t tests were used to assess the magnitude of differences
in the EQ-5D-3L and QOLIE-31P scores across groups.
Due to different study treatment period durations,
responsiveness was assessed using individual study data-
sets. The analysis population comprised all patients with no
missing EQ-5D-3L or QOLIE-31P data at baseline and
follow-up (week 12 or week 16) (n = 969, 86%).
Mapping
Mapping between the QOLIE-31P and the EQ-5D-3L was
a secondary study objective that was contingent on the
psychometric analysis results. However, psychometric
results indicated that mapping was not appropriate based
on strength of correlations, ability to distinguish between
groups with known differences and responsiveness and this
was confirmed in separate mapping assessment (see Online
Supplement 1).
All the validity analyses were undertaken using Stata
12.2 (StataCorp LP, College Station, TX, USA).
Results
Overall, 1095 patients had both EQ-5D-3L and QOLIE-
31P data available. Across the three studies, mean age of
the population was 36.8–39.2 years, there were marginally
more males than females, and the majority were Caucasian
(Table 1). Median focal seizure count/28 days at baseline
was 1.91–2.48 and the mean number of prior AEDs was
&3 across the three studies. Pooled mean (SD) EQ-5D-3L
utility score was 0.76 (0.23) at baseline and 0.78 (0.23) at
follow-up, while pooled mean (SD) QOLIE-31P total
scores were 55.6 (16.0) and 60 (16.1) at baseline and fol-
low-up, respectively. QOLIE-31P subscale scores are given
in Online Supplement 1.
Convergent validity
No strong correlations between EQ-5D-3L dimensions and
QOLIE-31P subscales were noted. At baseline, the EQ-5D-
3L usual activities dimension had weak-to-moderate cor-
relations with QOLIE-31P daily activities/social function-
ing (q = -0.319), emotional well-being (q = -0.316),
energy/fatigue (q = -0.290), and cognitive function sub-
scales (q = -0.286) (Table 2). EQ-5D-3L anxiety/de-
pression had moderate correlations with emotional well-
being (q = -0.455) and energy/fatigue (q = -0.334), but
the correlation with the seizure worry subscale was lower
than expected (q = -0.274). There were moderate corre-
lations between QOLIE-31P overall quality of life with
EQ-5D-3L usual activities (q = -0.327) and anxiety/de-
pression (q = -0.397). Most other correlations were weak
(q\ –0.3), with little evidence of association between
mobility, self-care, and pain/discomfort and the QOLIE-
31P subscales. There were no associations between EQ-
5D-3L or QOLIE-31P dimensions/subscales and seizure
frequency.
The EQ-5D-3L utility score had moderate correlations
with all QOLIE-31P subscales (q = 0.345–0.496) except
medication effects and seizure worry, which were weakly
correlated (q = 0.285 and 0.280, respectively). There was
no association between EQ-5D-3L utility score and seizure
frequency (q = -0.031).
Known group validity
Mean EQ-5D-3L utility scores varied with QOLIE-31P
groups, and differences across the groups were statistically
significant (p\ 0.001), with mainly small ES between
groups (Table 3). The presence of secondarily generalized
focal seizures (severe seizures) was associated with sta-
tistically significant lower EQ-5D-3L utility scores and
QOLIE-31P scores (both p\ 0.001). ES were small for
both EQ-5D-3L (-0.21) and QOLIE-31P (-0.32). Few
patients reported seizures on the day they completed the
instrument (n = 82). There were no statistically significant
differences between EQ-5D-3L and QOLIE-31P scores for
patients who reported seizures versus those who did not
(Table 3). Further assessment indicated there was no
monotonic relationship between the number of seizures
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that patients reported and either measure. There was some
evidence that patients with C5 prior AEDs had lower
health status based on a statistically significant difference
between EQ-5D-3L utility scores (p = 0.002). ES for this
difference were small (-0.22), but were larger than the
equivalent ES for QOLIE-31P total score (-0.11).
Across the three studies, a number of patients had full
health based on the EQ-5D-3L utility scores (24.9%).
However, the majority of these patients ([84%) reported
less than full health in QOLIE-31P total scores and sub-
scales (Table 4).
Responsiveness
There was little evidence at baseline of a large proportion
of respondents reporting the lowest levels in EQ-5D-3L
and QOLIE-31P dimensions/subscales. However, all five
EQ-5D-3L dimensions had a large proportion reporting no
problems (mobility: 83, 85, 81; self-care: 92, 93, 90%;
usual activities: 64, 62, 62%; pain/discomfort: 52, 49, 52%;
anxiety/depression: 43, 48, 43%) in the N01252, N01253
and N01254 studies, respectively. This is consistent with
the fact that mobility and self-care were expected to be less
Table 1 Baseline
demographics, epilepsy
characteristics, and baseline and
follow-up health-related quality
of life scores of patients
included in the analysis
Characteristic Brivaracetam study
N01252
(N = 355)
N01253
(N = 347)
N01254
(N = 393)
Pooled
(N = 1095)
Age [mean (SD)] 37.5 (13.0) 39.2 (12.1) 36.8 (11.5) 37.8 (12.2)
Male, [n (%)] 202 (56.9) 176 (50.7) 200 (50.9) 578 (52.8)
Race [n (%)]
Caucasian 280 (78.9) 248 (71.5) 232 (59.0) 760 (69.4)
Other 75 (21.2) 99 (28.5) 161 (41.0) 335 (30.6)
Baseline focal seizure frequency/28 days
Mean (SD) 4.01 (6.5) 6.37 (12.3) 5.06 (12.4) 5.13 (3.04)
Median (IQR) 1.91 (2.3) 2.48 (4.0) 2.21 (3.2) 2.14 (3.04)
Number of prior AEDs [mean (SD)] 3.5 (2.43) 3.3 (2.53) 3.1 (2.18) 3.3 (2.38)
EQ-5D-3L [mean (SD)]
Baseline 0.756 (0.234) 0.762 (0.226) 0.758 (0.234) 0.759 (0.232)
Follow-up 0.770 (0.241) 0.791 (0.221) 0.771 (0.229) 0.777 (0.230)
QOLIE-31P total score [mean (SD)]
Baseline 56.3 (16.3) 54.8 (17.1) 55.6 (14.7) 55.6 (16.0)
Follow-up 59.8 (15.8) 59.6 (17.6) 60.2 (15.0) 59.9 (16.1)
AED antiepileptic drug, IQR interquartile range, QOLIE-31P Quality of Life in Epilepsy Inventory, SD
standard deviation
Table 2 Convergent validity of EQ-5D-3L and QOLIE-31P using Spearman’s rank correlation at baseline (pooled data)
EQ-5D-3L dimensions Mobility Self-care Usual
activities
Pain/
discomfort
Anxiety/
depression
EQ-5D-3L utility
score
QOLIE-31P subscales (n = 1076)
Energy/fatigue -0.188 -0.115 -0.290 -0.232 -0.334 0.363
Emotional well-being -0.197 -0.132 -0.316 -0.255 -0.455 0.449
Daily activities/social functioning -0.163 -0.151 -0.319 -0.253 -0.234 0.345
Cognitive functioning -0.166 -0.177 -0.286 -0.238 -0.288 0.348
Medication effects -0.156 -0.074 -0.261 -0.229 -0.205 0.285
Seizure worry -0.106 -0.102 -0.261 -0.173 -0.274 0.280
Overall QoL -0.233 -0.127 -0.327 -0.274 -0.397 0.424
QOLIE-31P total score -0.234 -0.197 -0.413 -0.328 -0.427 0.496
Focal seizure frequency
(n = 1072)
0.040 ns 0.052 ns 0.065 0.026 ns -0.032 ns -0.031 ns
Cohen’s cut-offs: C0.5, strong; C0.3–\0.5, moderate;\0.3, weak
ns not significant, QoL quality of life, QOLIE-31P Quality of Life in Epilepsy Inventory
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problematic in this population. The QOLIE-31P subscales
did not have equivalent large proportions reporting no
problems except for medication effects in trial N01254
which was at 11%.
Mean changes in EQ-5D-3L dimensions were not sta-
tistically significant with small SRMs (SRM & 0.1 in all
three trials). Mean changes in QOLIE-31P subscales were
also small, but they were statistically significant (p\ 0.05)
Table 3 Known group validity of EQ-5D-3L and QOLIE-31P at baseline (pooled data)
Variable Groups N EQ-5D-3L utility score QOLIE-31P total score
Mean (SD) ES Test statistic/p value Mean (SD) ES Test statistic/p value
QOLIE-31P total
score groups
0–40 195 0.575 (0.28) F4,1090 = 73.8
p\ 0.001
41–50 210 0.697 (0.22) 0.53 – –
51–60 280 0.779 (0.20) 0.36 – –
61–70 208 0.832 (0.16) 0.23 – –
71–100 202 0.897 (0.15) 0.28 – –
Secondarily
generalized focal
seizures at baseline
No 734 0.775 (0.22) t1089 = 3.3
p\ 0.001
57.2 (15.4) t1089 = 5.0
p\ 0.001
Yes 357 0.726 (0.26) -0.21 52.1 (16.8) -0.32
Any seizure on day
of completion of
PRO
No 968 0.759 (0.23) t1048 = -0.98
p = 0.327
55.5 (16.1) t1048 = -1.5
p = 0.138
Yes 82 0.785 (0.24) 0.11 58.3 (15.7) 0.17
Baseline focal
seizure frequency/
week (log)
\1 418 0.765 (0.23) F2,1088 = 1.16
p = 0.314
56.3 (14.8) F2,1088 = 3.0
p = 0.050
1–\2 485 0.748 (0.24) -0.07 54.2 (17.1) –0.13
C2 188 0.775 (0.21) 0.12 57.1 (15.8) 0.18
Number of prior
AEDs in the past
5 years
0–1 331 0.780 (0.22) F2,1092 = 6.12
p = 0.002
56.3 (16.1) F2,1092 = 1.6
p = 0.202
2–4 479 0.768 (0.22) -0.05 55.9 (15.4) -0.02
C5 285 0.718 (0.25) -0.22 54.1 (17.0) -0.11
AED antiepileptic drug, ES effect sizes, PRO patient-reported outcome, QOLIE-31P Quality of Life in Epilepsy Inventory, SD standard deviation
Cohen’s cut-offs: C 0.8, large; C0.5–\0.8, medium; C0.2–\0.5, small
Table 4 QOLIE-31P scores for those with EQ-5D-3L utility score = 1 (pooled data)
Variable N Mean SD Median Min Max % with less than
max QOLIE score
QOLIE-31P subscales
Energy/fatigue 273 61.6 17.7 65.0 10.0 100 98.9
Emotional well-being 273 73.6 16.0 76.0 24.0 100 95.6
Daily activities/social functioning 273 67.0 22.5 66.0 0.0 100 86.4
Cognitive functioning 273 66.2 24.0 67.8 0.0 100 89.0
Medication effects 273 67.4 23.6 69.4 0.0 100 84.2
Seizure worry 273 54.6 27.6 59.3 0.0 100 94.5
Overall QoL 273 68.9 15.3 72.5 22.5 100 96.0
QOLIE total score 273 66.4 14.1 65.8 31.1 97.6 100
Max maximum, Min minimum, QoL quality of life, QOLIE-31P Quality of Life in Epilepsy Inventory, SD standard deviation
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and larger than EQ-5D-3L changes (SRM = 0.1–0.4))
except for medication effects (ES B 0.1). The largest SRM
in the QOLIE-31P was in seizure worry in studies N01252
and N01254 (SRM = 0.3 and 0.4, respectively). This
indicated minor improvements in health status and HRQoL
over time based on the disease-specific measure.
For responsiveness based on C50% reduction in focal
seizures, changes in EQ-5D-3L utility scores were higher
in responders vs non-responders in studies N01253
(ES = 0.41) and N01254 (ES = 0.11), but the difference
was statistically significant only in study N01253
(p = 0.002) (Table 5). In contrast, QOLIE-31P total score
change was statistically significantly higher in responders
in all three studies.
Assessment of response based on PGES and CGES
showed mostly no statistically significant differences
between groups with small ES in EQ-5D-3L utility scores
(Table 5). EQ-5D-3L utility scores differed based on
CGES groups for study N01253 and for PGES groups for
study N01254, but the latter was not a monotonic rela-
tionship. In contrast, QOLIE-31P total score change had a
linear association with the statistically significant
improvements reported in PGES and CGES (p\ 0.001),
except for CGES in study N01254.
Discussion
To assess the psychometric properties of the EQ-5D-3L in
patients with uncontrolled focal seizures, we used data
from three large Phase III, randomized, placebo-controlled
studies of brivaracetam, which is approved as adjunctive
therapy for focal seizures in adults with epilepsy. Epilepsy-
specific measures including the QOLIE-31P were used as
proxies for severity in convergent and known group anal-
ysis. The responsiveness of EQ-5D-3L and QOLIE-31P
was assessed based on their ability to detect differences in
treatment outcome groups.
Despite differences in the focus of the measures (generic
vs disease-specific), some association between measures
was expected. Correlation analyses confirmed some asso-
ciation between similar dimensions/subscales of each
instrument, although generally it was weak. Contrary to
expectations, the EQ-5D-3L usual activities and the
QOLIE-31P energy/fatigue and daily activities/social
functioning subscales were only weakly correlated. Simi-
larly, only a weak correlation was observed between EQ-
5D-3L anxiety/depression and QOLIE-31P seizure worry.
An earlier study reported that some patients with epilepsy
had difficulty answering the anxiety/depression dimension
of the EQ-5D-3L as they did not consider themselves to be
depressed [18]. Therefore, patients may not have consid-
ered seizure worry when completing the more general
anxiety/depression questions of the EQ-5D-3L. Dimen-
sions relating to mobility and self-care had little association
with QOLIE-31P subscales, and there were mainly weak
correlations between the pain dimension and QOLIE-31P
subscales. This might be expected, as these aspects of
HRQoL may not be impaired in patients with epilepsy. EQ-
5D-3L utility scores had weak-to-moderate correlations
with the QOLIE-31P subscales. Baseline seizure frequency
was neither correlated with the EQ-5D-3L dimensions or
utility scores, nor with QOLIE-31P subscale scores.
The EQ-5D-3L was able to reflect differences in groups
based on the QOLIE-31P total score. Neither EQ-5D-3L
nor QOLIE-31P scores reflected differences in baseline
number of seizures. Poor association between seizure fre-
quency and HRQoL may be due to the severity or timing of
seizures experienced. The episodic nature of epilepsy
means that seizure-free periods can be associated with
good HRQoL which decreases following a seizure [2].
Furthermore, EQ-5D-3L asks patients about their health on
the day of assessment, whereas QOLIE-31P covers the past
4 weeks and attempts to get a reading of ‘average’ HRQoL.
The presence of seizures on the day of questionnaire
completion was not negatively associated with HRQoL in
either measure; however, it was unknown whether seizures
occurred before or after questionnaire completion. The lack
of association between seizure frequency and HRQoL may
also be because large gains in HRQoL are only achieved
with seizure freedom [19], and this was achieved by rela-
tively few patients. However, there was evidence to sug-
gest that seizure severity may impact on HRQoL; patients
with secondarily generalized seizures, a proxy for more
severe seizures, had lower health status/HRQoL in both
EQ-5D-3L and QOLIE-31P, although the ES for EQ-5D-
3L were smaller. This observation is consistent with sev-
eral previous studies which found negative associations
between seizure severity and HRQoL [20].
EQ-5D-3L had large proportions reporting no problems
in the dimensions particularly in the mobility and self-care
dimensions (80–90%), which was not unexpected as
patients were not expected to have problems ‘walking
about’ or ‘washing and dressing’ themselves. In terms of
the overall EQ-5D-3L utility score, 24.9% were in full
health. The QOLIE-31P did not have comparable propor-
tions without problems. The vast majority of respondents
who reported a score of 1 in EQ-5D-3L reported scores
lower than 100 (best functioning) in the QOLIE-31P sub-
scales. This indicated that EQ-5D-3L dimensions were not
relevant or sensitive enough to assess the impact of epi-
lepsy-specific symptoms in this population. Where con-
cepts do overlap between the measures, QOLIE-31P has
more items and so may be able to capture these effects
better than the single items of the EQ-5D-3L. Langfitt et al.
[10] found that the SF-6D, which also has more items per
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Table 5 Responsiveness based on response to treatment status and clinician/patient evaluation of change at follow-up
Variable Groups N EQ-5D-3L utility score QOLIE-31P total score
Mean change
(SD)
ES ANOVA/t
test
(p value)
Mean
change (SD)
ES ANOVA/t
test
(p value)
N01252
Response to treatment (C50%
reduction in focal seizure
frequency)
Non-
responders
226 0.018 (0.24) t315 = 0.07
p = 0.947
2.01 (12.4) t315 = -3.7
p\ 0.001
Responders 91 0.016 (0.21) -0.01 7.94 (14.5) 0.45
PGES 1–4 96 0.016 (0.22) F3,308 = 0.09
p = 0.966
-1.07 (9.6) F3,308 = 9.25
p\ 0.001
5 87 0.027 (0.21) 0.05 3.67 (10.9) 0.36
6 73 0.009 (0.28) -0.08 6.58 (14.6) 0.22
7 56 0.020 (0.18) 0.05 9.13 (16.3) 0.19
CGES 1–4 108 0.051 (0.21) F3,312 = 1.7
p = 0.167
0.61 (12.1) F3,312 = 5.6
p\ 0.001
5 95 0.022 (0.22) -0.13 3.57 (11.2) 0.23
6 76 -0.023 (0.25) -0.20 5.96 (13.4) 0.18
7 37 0.005 (0.20) 0.12 9.73 (16.7) 0.29
N01253
Response (C50% reduction in focal
seizure frequency)
Non-
responders
234 0.000 (0.25) t303 = -3.1
p = 0.002
3.46 (12.6) t303 = -3.2
p = 0.001
Responders 71 0.103 (0.25) 0.41 9.71 (18.7) 0.43
PGES 1–4 97 -0.003 (0.21) F3,297 = 1.9
p = 0.123
-0.76 (11.5) F3,297 = 9.2
p\ 0.001
5 68 0.005 (0.33) 0.03 5.51 (11.6) 0.44
6 77 0.020 (0.19) 0.06 6.99 (13.3) 0.10
7 59 0.092 (0.28) 0.28 10.34 (19.1) 0.23
CGES 1–4 113 -0.004 (0.21) F3,297 = 2.8
p = 0.043
0.46 (12.9) F3,297 = 9.9
p\ 0.001
5 83 -0.004 (0.30) 0.00 4.91 (11.7) 0.31
6 65 0.054 (0.22) 0.23 6.93 (14.0) 0.14
7 40 0.111 (0.28) 0.23 13.64 (18.4) 0.47
N01254
Response (C50% reduction in focal
seizure frequency)
Non-
responders
244 0.010 (0.23) t342 = -0.92
p = 0.356
3.16 (12.0) t342 = -4.2
p\ 0.001
Responders 100 0.036 (0.26) 0.11 9.38 (14.0) 0.48
PGES 1–4 111 -0.021 (0.21) F3,335 = 3.6
p = 0.015
-0.20 (10.6) F3,335 = 19.3
p\ 0.001
5 92 0.048 (0.23) 0.28 3.29 (12.0) 0.28
6 88 -0.011 (0.24) -0.24 8.33 (12.0) 0.40
7 48 0.096 (0.33) 0.44 13.85 (13.3) 0.43
CGES 1–4 128 -0.016 (0.20) F3,341 = 1.9
p = 0.138
-1.12 (10.6) F3,341 = 21.7
p\ 0.001
5 86 0.010 (0.27) 0.11 5.12 (13.6) 0.48
6 91 0.059 (0.27) 0.20 11.36 (11.9) 0.48
7 40 0.039 (0.23) -0.08 9.17 (11.8) -0.17
PGES and CGES categories: 1–4, marked worsening to no change; 5, slight improvement; 6, moderate improvement; 7, marked improvement
Cohen’s cut-offs: C0.8, large; C0.5–\0.8, medium; C0.2–\0.5, small
ANOVA analysis of variance, CGES Clinician’s Global Evaluation Scale, ES effect sizes, PGES Patient’s Global Evaluation Scale, QOLIE-31P
Quality of Life in Epilepsy Inventory, SD standard deviation
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dimension and similar dimensions (social, role functioning,
energy, and emotional well-being), performed better than
the EQ-5D-3L.
In terms of responsiveness, the EQ-5D-3L and QOLIE-
31P dimension/subscale scores all showed positive change
over the trial period, but only QOLIE-31P subscales had
statistically significant changes. The SRMs were smaller for
EQ-5D-3L utility score than for QOLIE-31P (0.1 vs.
0.1–0.4), indicating that small changes in the population
were captured by some of the QOLIE-31P subscales but not
by the EQ-5D-3L dimensions. Responsiveness based on
50% seizure frequency reduction indicated small ES in EQ-
5D-3L utility and QOLIE-31P total scores (-0.01 vs. 0.45).
The efficacy gain in terms of seizure frequency in this pop-
ulation is more modest than in less refractory patients and, as
noted, few patients achieve seizure freedom; as such, it may
be more difficult to show improvement in HRQoL [19, 21].
In addition, meaningful changes in seizure frequency, coping
and lifestyle as a consequence of treatment efficacy may not
be reflected in HRQoL outcomes in studies of short duration
[22]. In contrast to the QOLIE-31P, change in EQ-5D-3L
utility scores was largely not associated with patient and
clinician evaluations of improvement. These results suggest
that even if the outcome achieved in this population was
modest, the QOLIE-31P detected some improvements that
the EQ-5D-3L was not sensitive enough to reflect.
The psychometric analyses indicated that QOLIE-31P
would be poor predictors of EQ-5D-3L due to the lack of
sufficient overlap between measures evidenced by lower
sensitivity of the EQ-5D-3L. This highlights the impor-
tance of assessing that generic preference-based measures
are appropriate in the population of interest in terms of
psychometric properties before carrying out mapping
analysis. However, the applicability of the generic measure
in the patient population concerned is not always reported
in mapping studies.
Overall, the results suggest that although there is some
association between the EQ-5D-3L and the QOLIE-31P, this
is not sufficient to capture changes over time to the same
degree, as the latter measure includes epilepsy-specific
concepts such as seizure worry. The existing disease-specific
measures, such as the QOLIE-31P, could be converted into a
preference-based measure, which could then be applied to
existing datasets without utility values. Alternatively, other
more broad generic HRQoL measures could be used in
mapping studies (e.g. the SF-36 and thus the SF-6D). Finally,
utility values could be generated from an existing epilepsy-
specific QALY measure, such as the Quality of Life in Newly
Diagnosed Epilepsy Instrument 6 dimensions (NEWQOL-
6D), which is derived from the NEWQOL [23, 24]. Values
for NEWQOL-6D health states were found to be similar in
patients and the general population, suggesting that using
general population utility weights to estimate QALYs is
appropriate and generally represents patient preferences
[24]. If the measure proves to be psychometrically valid in
patients with uncontrolled focal seizures, the NEWQOL-6D
could be used as an alternative to generate QALYs [24].
A number of studies have assessed the performance of
EQ-5D-3L in populations with epilepsy [10, 25, 26].
Overall, results support the findings of this study in that
some EQ-5D-3L dimensions may be relevant to a popu-
lation with uncontrolled focal seizures. However, outcomes
such as seizure control may not be as closely associated
with the EQ-5D-3L. Differences in levels of seizure
severity and interventions make it difficult to compare
these studies directly. One study, which assessed the rela-
tionship between seizure frequency and preference-based
HRQoL, found that in patients with recurrent seizures,
seizure frequency was not monotonically related to pref-
erence-based HRQoL, with substantial overlap across dif-
ferent seizure frequency categories, thereby mirroring
some of the findings in this study [27].
The analyses presented in this study provide important
information on the performance of EQ-5D-3L in a patient
population with uncontrolled focal seizures; however, there
are a number of limitations. The studies used in the anal-
ysis were designed to assess the efficacy, safety and tol-
erability of adjunctive brivaracetam; assessment of HRQoL
was an exploratory objective, and this may have impacted
on the analysis of HRQoL. The study populations were
based on clinical (e.g. seizure frequency) rather than
HRQoL criteria; therefore, their HRQoL data may not be
applicable to the overall population of patients with
uncontrolled focal seizures. Furthermore, the nature of the
instruments themselves may affect results as the QOLIE-
31P covers the previous 4 weeks, whereas EQ-5D-3L
focuses on a single day, which may exclude typical
HRQoL effects that occur over a period of time.
In summary, while some EQ-5D-3L dimensions over-
lapped with similar concepts in the disease-specific
QOLIE-31P, the content of the measure was unable to
capture self-reported epilepsy-specific concerns or to
reflect change over time. Given the lack of correlation and
joint responsiveness between the measures, using the EQ-
5D-3L for cost-effectiveness analysis including from
mapping is not recommended. A disease-specific prefer-
ence-based measure may offer an alternative.
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